Teva Pharmaceutical Industries (TEVA) said that it anticipates its 2025 diluted EPS will be at the higher end of its previously announced range of $2.55-$2.65. Consensus is $2.63.
The Israel-based drugmaker also said it expects revenues to be at the lower end of the $16.8M-$17M range. Consensus is $16.92M.
Teva also noted that free cash flow is expected in the higher end of its guidance, while adjusted EBITDA is expected in the midpoint.
Q4 and full-year financial results are scheduled for release on Jan. 28.
